Article
Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
The journal of pathology. Clinical research - 1 Jan 2021
Fujii Keiichiro, Sakamoto Yuma, Masaki Ayako, Murase Takayuki, Tashiro Yukie, Yonekura Kentaro, Utsunomiya Atae, Ito Asahi, Kusumoto Shigeru, Iida Shinsuke, Ueda Ryuzo, Ishida Takashi, Inagaki Hiroshi
Abstract excerpt
Mogamulizumab targets extracellular N-terminal domain of CCR4, which is expressed in most adult T-cell leukemia/lymphoma (ATL) cases. Recently, we reported that CCR4 C-terminal gain-of-function mutations were frequent in ATL cases, and a subgroup with these mutations who were treated without allogenic hematopoietic stem cell transplantation (HSCT) and with mogamulizumab-containing [HSCT (-) and mogamulizumab (+)]...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.